Evolving War of PDE5 Inhibitors

Since 비아그라 정품 was released in Korea in 1999, the development process of domestic oral erectile dysfunction drugs has been a field of competition for oral erectile dysfunction drugs around the world. It has continued to evolve and develop through the fierce competition for survival in the pharmaceutical industry, which is reminiscent of war.

The start of this competitive evolution began in 2003 when Tadalafil (Cialis) of Lilly and Vardenafil (Levitra) of Bayer started domestic sales, and 비아그라 정품 met the first round of the battle for oral erectile dysfunction drugs. An ideal oral erection stimulant should be able to be used in combination with other drugs because of its rapid action, excellent erectile effect and longevity of erection, reproducibility of a certain effect, low side effects, and low drug interaction. It should have various characteristics, such as being able to receive and having a low price. In this period, the efficacy and safety of the three oral erection stimulants of the single dose method were mainly emphasized, and the pharmacokinetic superiority of each drug was emphasized.

Therefore, regarding the efficacy and reproducibility of drugs, the characteristics of each drug were emphasized, such as fast-acting using Tmax and T1/2, duration of action using T1/2, and AUC (area under the curve) on the PK curve, and enzyme selectivity using IC50. As for safety, data on enzyme selectivity, drug metabolism, and drug interaction were presented.

In particular, he emphasized that Cialis is a long-acting agent with a longer duration of action compared to two drugs, and not only can maintain an erection for a long time but also does not require daily consumption. It emphasized the rapid onset of effects as an advantage and set it up as a sales strategy.

On the other hand, 비아그라 정품, as an aid, had demonstrated efficacy and patient satisfaction in terms of efficacy and safety accumulated from sales use for about 5 years at the time. In fact, Viagra was released in 25, 50, 100mg, Cialis 5-10-20mg, and Levitra 10mg and 20mg. was recommended to be reduced.

In addition, if there is a burden on the price or if the degree of erectile dysfunction is not severe, the tablet may be divided arbitrarily.

Meanwhile, in Korea, in 2005, Dong-A Pharm developed Udenafil (Zydena), which had been developed since 1998, as the first domestically produced product, and its price competitiveness was presented as an advantage. While it is a war of three types of erection stimulants, in Korea, five types of erection stimulants are engaged in a more intense local battle.

At this time, the highest dose began to be prescribed as the first dose along with pharmaceutical companies' marketing strategy to increase market share due to the safety already proven in many patients. The concept of the has disappeared.

Meanwhile, PDE5 inhibitor is present in the smooth muscle of almost all organs of the human body, and research results have been published in various fields due to the active route of the NO pathway. permission has been obtained For this reason, in 2005-2007, academia presented various evidence that could expand the treatment area of ​​PDE5 inhibitor, an oral erectile dysfunction drug, to diseases other than erectile dysfunction.

As demonstrated by Pfizer's Revatio, the new usage of PDE5-Is as an oral drug for erectile dysfunction is safe even after long-term administration. It can be applied to the treatment of factors.